Bringing you live news and features since 2006 

Oppenheimer appoints MD and senior analyst


Oppenheimer & Co has expanded its Life Sciences research team with the addition of Frank Brisebois as Managing Director and Senior Analyst. “These are dynamic times in the Life Sciences sector, with new therapies and technological innovations poised to revolutionise entire business models,” says John Parks, Managing Director & Director of Equity Research at Oppenheimer. “The Life Sciences sector has historically been a strong area of focus for Oppenheimer. Frank’s experience and insights will reinforce our Life Sciences expertise during a time of significant change, while expanding our research offerings in ways that strengthen and grow our Life Sciences team.”

With over a decade of relevant experience, Brisebois is based in Boston, and is focused on the sub-sectors of Ophthalmology, Audiology, Pain/CNS, Cannabis Derivatives, and Digital Medicine. Prior to joining Oppenheimer, he was a Senior Research Analyst at Craig-Hallum Capital covering Biotechnology and Biopharmaceuticals. He also previously worked at Laidlaw Capital Markets for five years and started his career at healthcare specialty firm Summer Street Research Partners. He holds a Bachelor of Arts in Molecular Biology from Colgate University, and a Master of Science in Pharmaceutical Sciences from the University of Montreal.
Brisebois says: “I’m excited to join Oppenheimer’s Life Sciences research team, which has distinguished itself over the years with its strong insights and analysis about this sector. I look forward to partnering closely with my new colleagues to continue to strengthen the firm’s longstanding expertise in Life Sciences.”

Latest News

Figment Europe, a provider of institutional staking infrastructure, writes that it is solidifying its presence in the heart of Europe’s..
Saving and investing app, Moneybox, has doubled the number of ETFs available on the platform, in the light of ‘growing..
Global X ETFs has announced the appointment of Ryan O'Connor as its Chief Executive Officer effective as of April 8, 2024. ..
Value-driven structured credit investing firm, Angel Oak Capital Advisors, LLC, has announced the completed conversions of two of its mutual..

Related Articles

Ryan McCormack, Invesco
This year sees the 25th anniversary of Invesco’s QQQ, the USD240 billion ETF – the fifth largest ETF in the...
The European ETF market achieved a record 28 per cent growth – reaching over USD1.8 trillion assets under management (AUM)...
Sal Esposito, Zacks Investment Management
Zacks Investment Management started doing investment research in 1978 and in 1992 started its investment management arm, initially with SMAs...
Jeremy Senderowicz, Vedder Price
Jeremy Senderowicz, a member of the Investment Services Group at law firm Vedder Price, has witnessed a steady upswing in...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by